TD Cowen Maintains Buy Rating on Passage Bio (PASG)

Passage Bio (PASG) received a Buy rating from TD Cowen analyst Brendan Smith. The company's shares opened at $5.52. Smith has a 2-star analyst rating with a 40.00% success rate. The analyst consensus on Passage Bio is a Strong Buy with an average price target of $120.00. The company has a market cap of $17.5M and a P/E ratio of -0.31.

Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company specializing in neurodegenerative diseases, received a Buy rating from TD Cowen analyst Brendan Smith. The company's shares opened at $5.52 on July 2, 2025. Smith, who has a 2-star analyst rating with a 40.00% success rate, has recommended Passage Bio as a Strong Buy with an average price target of $120.00.

The company's market cap stands at $17.5 million, with a P/E ratio of -0.31. Passage Bio's recent financial results and clinical progress have been encouraging, with the company reporting a cash position of $57.6 million, reduced R&D expenses to $5.8 million from $10.4 million YoY, and a narrowed net loss of $9.4 million compared to $16.0 million YoY [1].

Key upcoming milestones for Passage Bio include seeking regulatory feedback on the manufacturing process in the second half of 2025 and trial design in the first half of 2026. Additionally, the company plans to report updated interim data from Dose 2 in the first half of 2026. These developments are expected to further strengthen Passage Bio's position in the gene therapy innovation landscape.

The analyst consensus on Passage Bio is a Strong Buy, reflecting the positive outlook on the company's potential to deliver breakthrough treatments for rare central nervous system disorders. Despite the current market cap and P/E ratio, the strong buy rating suggests that investors are bullish on Passage Bio's long-term prospects.

References:
[1] https://www.stocktitan.net/news/PASG/